WO2001063293A3 - Diagnosis and treatment of schizophrenia - Google Patents

Diagnosis and treatment of schizophrenia Download PDF

Info

Publication number
WO2001063293A3
WO2001063293A3 PCT/GB2001/000783 GB0100783W WO0163293A3 WO 2001063293 A3 WO2001063293 A3 WO 2001063293A3 GB 0100783 W GB0100783 W GB 0100783W WO 0163293 A3 WO0163293 A3 WO 0163293A3
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
spis
treatment
diagnosis
detectable
Prior art date
Application number
PCT/GB2001/000783
Other languages
French (fr)
Other versions
WO2001063293A8 (en
WO2001063293A2 (en
Inventor
Herath Mudiyanselage At Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Original Assignee
Oxford Glycosciences Uk Ltd
Herath Mudiyanselage At Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004415A external-priority patent/GB0004415D0/en
Application filed by Oxford Glycosciences Uk Ltd, Herath Mudiyanselage At Herath, Rajesh Bhikhu Parekh, Christian Rohlff filed Critical Oxford Glycosciences Uk Ltd
Priority to EP01905991A priority Critical patent/EP1259818A2/en
Priority to AU2001233954A priority patent/AU2001233954A1/en
Publication of WO2001063293A2 publication Critical patent/WO2001063293A2/en
Publication of WO2001063293A8 publication Critical patent/WO2001063293A8/en
Publication of WO2001063293A3 publication Critical patent/WO2001063293A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides methods and compositions for screening, diagnosis and prognosis of Schizophrenia, for monitoring the effectiveness of Schizophrenia treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. Schizophrenia-Associated Features (SFs), detectable by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides Schizophrenia-Associated Protein Isoforms (SPIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising SPIs, antibodies immunospecific for SPIs, and kits comprising the aforesaid.
PCT/GB2001/000783 2000-02-24 2001-02-23 Diagnosis and treatment of schizophrenia WO2001063293A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01905991A EP1259818A2 (en) 2000-02-24 2001-02-23 Diagnosis and treatment of schizophrenia
AU2001233954A AU2001233954A1 (en) 2000-02-24 2001-02-23 Proteins, genes and their use for diagnosis and treatment of schizophrenia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0004415.6 2000-02-24
GB0004415A GB0004415D0 (en) 2000-02-24 2000-02-24 Proteins and their use for diagnosis and treatment of schizophrenia
US75039500A 2000-12-28 2000-12-28
US09/750,395 2000-12-28

Publications (3)

Publication Number Publication Date
WO2001063293A2 WO2001063293A2 (en) 2001-08-30
WO2001063293A8 WO2001063293A8 (en) 2001-10-18
WO2001063293A3 true WO2001063293A3 (en) 2002-04-11

Family

ID=26243725

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2001/000783 WO2001063293A2 (en) 2000-02-24 2001-02-23 Diagnosis and treatment of schizophrenia
PCT/GB2001/000792 WO2001062785A2 (en) 2000-02-24 2001-02-23 Protein and gene and their use for diagnosis and treatment of schizophrenia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/000792 WO2001062785A2 (en) 2000-02-24 2001-02-23 Protein and gene and their use for diagnosis and treatment of schizophrenia

Country Status (3)

Country Link
EP (2) EP1259818A2 (en)
AU (2) AU2001233954A1 (en)
WO (2) WO2001063293A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2003028543A2 (en) * 2001-10-03 2003-04-10 Pfizer Products Inc. Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
US7052849B2 (en) * 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US20030100012A1 (en) * 2001-11-23 2003-05-29 George Jackowski Plasma protease C1 biopolymer markers predictive of alzheimers disease
CA2476765A1 (en) 2002-02-21 2003-09-04 Quark Biotech, Inc. Methods of preventing or treating brain ischemia or brain injury
CN1300588C (en) * 2005-02-28 2007-02-14 上海交通大学 Method for acquiring plasma specific protein for schizophrenia diagnosis and use thereof
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
WO2010079511A2 (en) * 2008-12-27 2010-07-15 Pawan Saharan Mammalian colostrum derived nanopeptides for broadspectrum viral and recurrent infections with a method of isolation thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033480A1 (en) * 1994-06-07 1995-12-14 The Government Of The United States Of America, Re Pigment epithelium-derived factor: characterization, genomic organization and sequence of the pedf gene
WO1998011222A1 (en) * 1996-09-13 1998-03-19 The Mount Sinai School Of Medicine Of The City University Of New York Screening methods for compounds useful in the treatment of schizophrenia
WO1998040748A1 (en) * 1997-03-14 1998-09-17 Neuromark Diagnosing neurologic disorders
WO1998042723A1 (en) * 1997-03-27 1998-10-01 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
WO1999011796A1 (en) * 1997-09-05 1999-03-11 Acorda Therapeutics Hnk-1 sulfotransferase and methods of use therefor
WO1999014328A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000023784A2 (en) * 1998-10-21 2000-04-27 Chen, Hong Method of detecting risk of type ii diabetes based on mutations found in carboxypeptidase e
WO2000055173A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human breast and ovarian cancer associated gene sequences and polypeptides
WO2001025268A1 (en) * 1999-10-04 2001-04-12 Schrotz King Petra Human seizure related proteins
EP1101820A1 (en) * 1999-11-15 2001-05-23 MERCK PATENT GmbH Pentraxin I and Pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767252A (en) * 1996-04-08 1998-06-16 The Johns Hopkins University School Of Medicine Neuronal cell growth factor, Narp

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033480A1 (en) * 1994-06-07 1995-12-14 The Government Of The United States Of America, Re Pigment epithelium-derived factor: characterization, genomic organization and sequence of the pedf gene
WO1998011222A1 (en) * 1996-09-13 1998-03-19 The Mount Sinai School Of Medicine Of The City University Of New York Screening methods for compounds useful in the treatment of schizophrenia
WO1998040748A1 (en) * 1997-03-14 1998-09-17 Neuromark Diagnosing neurologic disorders
WO1998042723A1 (en) * 1997-03-27 1998-10-01 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
WO1999011796A1 (en) * 1997-09-05 1999-03-11 Acorda Therapeutics Hnk-1 sulfotransferase and methods of use therefor
WO1999014328A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000023784A2 (en) * 1998-10-21 2000-04-27 Chen, Hong Method of detecting risk of type ii diabetes based on mutations found in carboxypeptidase e
WO2000055173A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human breast and ovarian cancer associated gene sequences and polypeptides
WO2001025268A1 (en) * 1999-10-04 2001-04-12 Schrotz King Petra Human seizure related proteins
EP1101820A1 (en) * 1999-11-15 2001-05-23 MERCK PATENT GmbH Pentraxin I and Pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DISCIPIO, RICHARD G. ET AL: "The structure of human complement component C7 and the C5b-7 complex", J. BIOL. CHEM. (1988), 263(1), 549-60, XP001009867 *
FURLEY A J ET AL: "THE AXONAL GLYCOPROTEIN TAG-1 IS AN IMMUNOGLOBULIN SUPERFAMILY MEMBER WITH NEURITE OUTGROWTH-PROMOTING ACTIVITY", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 61, no. 1, 6 April 1990 (1990-04-06), pages 157 - 170, XP001016334, ISSN: 0092-8674 *
GEBHARD W ET AL: "CDNA CLONING AND COMPLETE PRIMARY STRUCTURE OF THE SMALL, ACTIVE SUBUNIT OF HUMAN CARBOXYPEPTIDASE N (KININASE 1)", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 178, no. 3, January 1989 (1989-01-01), pages 603 - 607, XP001025505, ISSN: 0014-2956 *
HASLER T H ET AL: "CDNA CLONING, STRUCTURAL FEATURES, AND EUCARYOTIC EXPRESSION OF HUMAN TAG-1/AXONIN-1", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 211, no. 1/2, January 1993 (1993-01-01), pages 329 - 339, XP001025504, ISSN: 0014-2956 *
KOZAKI K ET AL: "ISOLATION, PURIFICATION AND CHARACTERIZATION OF A COLLAGEN-ASSOCIATED SERPIN, CASPIN, PRODUCED BY MURINE COLON ADENOCARCINOMA CELLS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 24, 1998, pages 15125 - 15130, XP001023973, ISSN: 0021-9258 *
KRUPNIK V E ET AL: "Functional and structural diversity of the human Dickkopf gene family", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 238, no. 2, 1 October 1999 (1999-10-01), pages 301 - 313, XP002140768, ISSN: 0378-1119 *
OMEIS I A ET AL: "MOUSE AND HUMAN NEURONAL PENTRAXIN 1 (NPTX1): CONSERVATION, GENOMICSTRUCTURE, AND CHROMOSOMAL LOCALIZATION", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 36, no. 3, 1996, pages 543 - 545, XP000909636, ISSN: 0888-7543 *
SCHLIMGEN A K ET AL: "NEURONAL PENTRAXIN, A SECRETED PROTEIN WITH HOMOLOGY TO ACUTE PHASEPROTEINS OF THE IMMUNE SYSTEM", NEURON, CAMBRIDGE, MA, US, vol. 14, 1995, pages 519 - 526, XP000909700 *
TSIOTRA P ET AL: "ISOLATION OF THE CDNA AND CHROMOSOMAL LOCALIZATION OF THE GENE (TAX1) ENCODING THE HUMAN AXONAL GLYCOPROTEIN TAG-1", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 18, no. 3, 1994, pages 562 - 567, XP001025514, ISSN: 0888-7543 *
TSUJI, T. ET AL.: "A REIC Gene Shows Down-Regulation in Human Immortalized Cells and Human Tumor-Derived Cell Lines", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 268, 5 February 2000 (2000-02-05), pages 20 - 24, XP001016362 *

Also Published As

Publication number Publication date
AU2001233954A1 (en) 2001-09-03
WO2001062785A3 (en) 2002-01-31
EP1259607A2 (en) 2002-11-27
WO2001063293A8 (en) 2001-10-18
EP1259818A2 (en) 2002-11-27
AU2001237543A1 (en) 2001-09-03
WO2001063293A2 (en) 2001-08-30
WO2001062785A2 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2002082075A3 (en) Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
CA2421007A1 (en) Method for detection of htr and htert telomerase-associated rna in plasma or serum
ATE353974T1 (en) METHODS, COMPOSITIONS AND KITS FOR IDENTIFYING AND MONITORING BREAST CANCER
WO2003087831A3 (en) Proteins involved in breast cancer
BRPI0413495A (en) prion-specific peptide reagents and their uses
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO1999047925A3 (en) Methods and compositions for diagnosis of rheumatoid arthritis
DE60137264D1 (en) MONOCLONAL ANTIBODIES AND CELL SURFACE ANTIGENS FOR THE DETECTION AND TREATMENT OF SMALL CELL LUNG CANCER (SCLC)
WO2005056585A3 (en) Sars coronavirus s proteins and uses thereof
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2001063293A8 (en) Diagnosis and treatment of schizophrenia
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
WO2002090974A3 (en) Method for detecting progredient chronic dementia, and associated peptides and detection reagents
WO2001063294A3 (en) Diagnosis of bipolar affective disorder (bad) and unipolar depression
WO2001069261A3 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
WO2003048734A3 (en) Detection of matrix metalloproteinase rna in plasma and serum
WO2004051269A3 (en) Ciz1 replication protein
ATE255229T1 (en) DPI-6, A THERAPEUTIC BIOMARKER IN NEUROLOGICAL DISEASES
WO2001064876A3 (en) Human schizophrenia gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 35/2001 UNDER (30) REPLACE "28.02.2000" BY "28.12.2000"

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001905991

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001905991

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001905991

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP